This is a PDF-only article. The first page of the PDF of this article appears above.
In this issue
Jump to section
Related Articles
Cited By...
- Cure of Micrometastatic B-Cell Lymphoma in a SCID Mouse Model Using 213Bi-Anti-CD20 Monoclonal Antibody
- [18F]-Labeled PARP-1 PET Imaging of PSMA Targeted Alpha Particle Radiotherapy Response
- Radiation Safety Considerations and Clinical Advantages of {alpha}-Emitting Therapy Radionuclides
- Efficient 1-Step Radiolabeling of Monoclonal Antibodies to High Specific Activity with 225Ac for {alpha}-Particle Radioimmunotherapy of Cancer
- Anti-Prostate-Specific Membrane Antigen Liposomes Loaded with 225Ac for Potential Targeted Antivascular {alpha}-Particle Therapy of Cancer
- Ex Vivo Activity Quantification in Micrometastases at the Cellular Scale Using the {alpha}-Camera Technique
- Sequential Cytarabine and {alpha}-Particle Immunotherapy with Bismuth-213-Lintuzumab (HuM195) for Acute Myeloid Leukemia
- Radioimmunotherapy of Breast Cancer Metastases with {alpha}-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90Y
- Drug-Resistant AML Cells and Primary AML Specimens Are Killed by 111In-Anti-CD33 Monoclonal Antibodies Modified with Nuclear Localizing Peptide Sequences
- Preclinical Evaluation of the {alpha}-Particle Generator Nuclide 225Ac for Somatostatin Receptor Radiotherapy of Neuroendocrine Tumors
- Radioimmunotherapy with {alpha}-Particle-Emitting 213Bi-C-Functionalized trans-Cyclohexyl-Diethylenetriaminepentaacetic Acid-Humanized 3S193 Is Enhanced by Combination with Paclitaxel Chemotherapy
- Potent Antitumor Activity of an Auristatin-Conjugated, Fully Human Monoclonal Antibody to Prostate-Specific Membrane Antigen
- Fractionated Locoregional Low-Dose Radioimmunotherapy Improves Survival in a Mouse Model of Diffuse-Type Gastric Cancer Using a 213Bi-Conjugated Monoclonal Antibody
- Melanoma Therapy via Peptide-Targeted {alpha}-Radiation
- Efforts to Control the Errant Products of a Targeted In vivo Generator
- The Promise of Targeted {alpha}-Particle Therapy
- Targeting of HER2 Antigen for the Treatment of Disseminated Peritoneal Disease
- Treatment of Neuroblastoma Meningeal Carcinomatosis with Intrathecal Application of {alpha}-Emitting Atomic Nanogenerators Targeting Disialo-Ganglioside GD2
- Alpha-Particle Emitting Atomic Generator (Actinium-225)-Labeled Trastuzumab (Herceptin) Targeting of Breast Cancer Spheroids: Efficacy versus HER2/neu Expression
- Immunotherapeutic Approaches for Hematologic Malignancies
- Locoregional {alpha}-Radioimmunotherapy of Intraperitoneal Tumor Cell Dissemination Using a Tumor-specific Monoclonal Antibody
- Targeted Actinium-225 in Vivo Generators for Therapy of Ovarian Cancer
- Pharmacokinetics and Biodistribution of 86Y-Trastuzumab for 90Y Dosimetry in an Ovarian Carcinoma Model: Correlative MicroPET and MRI
- Selective T-cell ablation with bismuth-213-labeled anti-TCR{alpha}{beta} as nonmyeloablative conditioning for allogeneic canine marrow transplantation
- Pretarget radiotherapy with an anti-CD25 antibody-streptavidin fusion protein was effective in therapy of leukemia/lymphoma xenografts
- Targeted alpha particle immunotherapy for myeloid leukemia
- Bismuth 213-labeled anti-CD45 radioimmunoconjugate to condition dogs for nonmyeloablative allogeneic marrow grafts
- Tumor Therapy with Targeted Atomic Nanogenerators
- Comparative Cellular Catabolism and Retention of Astatine-, Bismuth-, and Lead-Radiolabeled Internalizing Monoclonal Antibody
- Highly Specific Tumor Binding of a 213Bi-labeled Monoclonal Antibody against Mutant E-Cadherin Suggests Its Usefulness for Locoregional {{alpha}}-Radioimmunotherapy of Diffuse-Type Gastric Cancer
- Response of LNCaP Spheroids after Treatment with an {{alpha}}-Particle Emitter (213Bi)-labeled Anti-Prostate-specific Membrane Antigen Antibody (J591)
- Parametric Images of Antibody Pharmacokinetics in Bi213-HuM195 Therapy of Leukemia
- An {{alpha}}-Particle Emitting Antibody ([213Bi]J591) for Radioimmunotherapy of Prostate Cancer